At each post-Voraxaze assessment time point, the median MTX concentration was <0.54 μM, corresponding to a median reduction of ≥97% from pre-Voraxaze measurements.2
Voraxaze® (glucarpidase) reduced plasma MTX concentrations by ≥97% within 15 minutes in all 22 treatment-evaluable patients.1
91% (20/22) of patients who received Voraxaze achieved a >95% reduction in plasma MTX concentrations within 15 minutes of administration that lasted for up to 8 days.1
77% (10/13) of patients with MTX levels ≤50 μM who received Voraxaze achieved a reduction of MTX levels to ≤1 μM within 15 minutes of administration that lasted for up to 8 days.1
*Results are from a single-arm, open-label study in 22 treatment-evaluable patients with markedly delayed MTX clearance secondary to acute kidney injury. The primary endpoint of the study was the proportion of patients achieving an MTX plasma concentration of ≤1 μM at 15 minutes that was sustained for up to 8 days following the initial injection.1
Incidence of Grade 4 toxicity was significantly lower with early administration of Voraxaze.3
Incidence of mortality was significantly lower with early administration of Voraxaze.4
Treatment with Voraxaze vs standard supportive care alone reduces plasma MTX within 15 minutes vs 11 ± 3 days.1,5-7
Not every patient requires Voraxaze, but experts have assembled recommendations to help guide treatment.
Explore guidelines for the use and stocking of Voraxaze so that you’re prepared in an emergency.